CLINICAL TRIALS PROFILE FOR BMS-986256
✉ Email this page to a colleague
Clinical Trials for BMS-986256
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT03634995 ↗ | An Investigational Study to Evaluate the Effects of Experimental Medication BMS-986256 in Healthy Participants | Completed | Bristol-Myers Squibb | Phase 1 | The purpose of this study is to evaluate the effects of the experimental medication BMS-986256 in healthy participants. |
| NCT03950960 ↗ | A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of BMS-986256 in Healthy Participants | Completed | Bristol-Myers Squibb | Phase 1 | The purpose of this study is to evaluate the effect of cytochrome P450 3A4 inhibition by Itraconazole on the pharmacokinetics of BMS-986256. |
| NCT04016753 ↗ | A Study Measuring the Effectiveness of BMS-986256 Combined With Oral Contraceptive in Healthy Female Participants | Active, not recruiting | Bristol-Myers Squibb | Phase 1 | A comparative study of BMS-986256 with a combined oral contraceptive in healthy female participants to determine the effectiveness when taken together |
| NCT04039373 ↗ | Effects of BMS-986256 at Steady State on the Single Dose Pharmacokinetics of Mycophenolate Mofetil | Completed | Bristol-Myers Squibb | Phase 1 | A Study to Investigate BMS-986256 at steady state and its effect on Mycophenolate Mofetil exposure in Healthy Male Participants |
| NCT04269356 ↗ | Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants | Recruiting | Bristol-Myers Squibb | Phase 1 | The purpose of this study is to assess the way the body absorbs, distributes, breaks down and eliminates radioactive BMS-986856 in healthy males. |
| NCT04470778 ↗ | Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants | Completed | Bristol-Myers Squibb | Phase 1 | The purpose of this study is to investigate the effect of gastric pH changes due to famotidine administration on the drug levels of prototype BMS-986256 tablet formulation in healthy participants. |
| NCT04493541 ↗ | A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus | Recruiting | Bristol-Myers Squibb | Phase 1 | The purpose of this study is to assess the safety and drug levels of BMS-986256 in participants with cutaneous lupus erythematosus. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for BMS-986256
Condition Name
Clinical Trial Locations for BMS-986256
Trials by Country
Clinical Trial Progress for BMS-986256
Clinical Trial Phase
Clinical Trial Sponsors for BMS-986256
Sponsor Name
